News

XPENG P7+: A Revolutionary Electric Vehicle for Europe

XPENG P7+: A Revolutionary Electric Vehicle for Europe

XPENG P7+ Unveils Advanced Innovation at the Brussels Motor Show

XPENG, a prominent player in AI-driven smart electric vehicles, introduces the XPENG P7+ to European audiences at a leading motor show in Brussels. This groundbreaking model signifies a pivotal step in XPENG's European endeavors and symbolizes the ongoing shift towards brainpower in the automotive sector.

Commitment to Future-Ready Technology

Mr. He Xiaopeng, the esteemed Chairman and CEO of XPENG, emphasized the company's dedication, stating, "The launch of the XPENG P7+ reflects our relentless pursuit of providing advanced technology to a broader audience. With cutting-edge Turing chips and luxurious design, we are eager for drivers to engage with a vehicle designed for the next generation of intelligent mobility."

The XPENG P7+, powered by an innovative Turing AI chip architecture, boasts an impressive computing capability of up to 750 tera operations per second (TOPS). This revolutionary platform offers enhanced perception and rapid data processing, enabling sophisticated driver assistance systems (ADAS) across diverse real-world scenarios, all while laying a robust foundation for future software enhancements.

Intelligent Driving Experience

The AI-driven features of the P7+ ensure a seamless driving experience, enabling smooth lane changes, reliable cruising, and effortless parking even in intricate traffic situations. Safety is paramount, as evidenced by the head-up display (W-HUD) projecting key information directly into the driver’s view, enhancing both convenience and security.

Exceptional Design and Comfort

The XPENG P7+ not only excels in technology but also in design, with its elegant lines and athletic proportions. Measuring 5,071 mm in length, 1,937 mm in width, and 1,512 mm in height, this vehicle offers a generous luggage capacity of 573 litres, which can expand to an impressive 1,931 litres with rear seats folded down.

The interior of the P7+ radiates luxury, featuring premium materials such as a plush microfiber velour headliner and perforated Nappa leather upholstery, ensuring a refined ambiance. Moreover, the P7+ is engineered for quiet operation, integrating extensive sound insulation techniques that include targeted noise reduction measures and cutting-edge sound-absorbing elements.

Manufacturing and Availability in Europe

Production of the XPENG P7+ has successfully launched at Magna Steyr's facility in Graz, Austria, making it the third model from XPENG to be assembled in Europe after the New G6 and New G9.

Customer deliveries are set to commence in April, targeting 25 European markets, with starting prices around €43,990 for the RWD Standard Range, dependent on local market conditions.

XPENG's expanding presence in Europe is evidenced by the delivery of 22,787 vehicles in the previous year, marking a significant 126% increase from the prior year. Currently, XPENG operates in 26 European nations, supported by over 13 skilled importers and dealer partners. This growth is bolstered by the newly established XPENG Germany R&D center, which commenced operations in 2025, enhancing local innovation through engineering upgrades.

Discover XPENG's Vision

Founded in 2014, XPENG is committed to shaping the future of mobility through its cutting-edge electric vehicles and AI technology. With a mission to lead the intelligent electric vehicle revolution, XPENG focuses on integrating advancements in technology to enhance the user experience. The company develops advanced driver assistance technology (ADAS) and an intelligent in-car operating system, alongside core vehicle systems, all aimed at serving a tech-savvy customer base. XPENG's main operations reside in Guangzhou, China, while it has additional offices in global technology hubs including Silicon Valley and Amsterdam, further solidifying its international reach.

XPENG is publicly traded on the New York Stock Exchange under the ticker symbol XPEV and also on the Hong Kong Stock Exchange (HKEX: 9868).

Frequently Asked Questions

What is the XPENG P7+?

The XPENG P7+ is an advanced electric vehicle featuring cutting-edge AI technology aimed at enhancing intelligent mobility.

When will the P7+ be available in Europe?

Deliveries of the XPENG P7+ are expected to begin in April across various European markets.

What technology does the P7+ utilize?

The P7+ is powered by the Turing AI chip architecture, providing significant AI computing power for enhanced driving capabilities.

What materials are used in the P7+ interior?

The interior features premium materials, including a microfiber velour headliner and perforated Nappa leather seats for a luxury experience.

Where is the XPENG P7+ manufactured?

The P7+ is produced at Magna Steyr's facility in Graz, Austria, marking XPENG's commitment to local manufacturing in Europe.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Horowitz's $150M Boost for Nevada's First Children's Hospital

Updated Category News Views 97

Big Bucks and Bigger Hearts Boost Pediatric Care in Nevada The world isn't exactly short on folks looking to make a buck, but every so often, someone comes along and wants to make a difference instead. Enter Felicia and Ben Horowitz, handing over a staggering $150 million to Intermountain Health. This isn’t your garden-variety gift—it’s aimed at getting Nevada on...

Continue Reading
UCB's Endowment Marks New Era in Medicine Evaluation

Updated Category News Views 60

Stepping into a New Chapter for Medicine Evaluation UCB's latest move smacks of a strategic vision that's not just about immediate returns—it's a long game in pharmacoepidemiology. You don't see investors lining up for this news, but this chair at Brigham and Women's is bigger than it looks. By establishing the Emmanuel Janssen Endowed Chair, UCB is underpinning the...

Continue Reading
Steady Income Boosts FHLBank Boston's Growth Q3 2026

Updated Category News Views 50

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Continue Reading
Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

Updated Category News Views 14

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 28

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Patrick Ta Beauty Adds New Leadership to Expand Growth

Updated Category News Views 36

Angela Simpson and Carolyne Rapp Join the Ranks In the fast-paced world of beauty, where trends shift faster than a day trader’s mood, Patrick Ta Beauty is shaking things up with some heavyweight hires. Angela Simpson steps in as Chief Marketing Officer, and Carolyne Rapp takes the reins as Vice President of Creative. Maybe it’s just me, but when a brand ropes in pros...

Continue Reading
Lunit, Summit Tackle Tumor Analysis with AI Platform

Updated Category News Views 168

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Continue Reading
Hyperliquid Reports Q3 2026 Results with Webcast Insights

Updated Category News Views 74

Unlocking Hyperliquid’s Third Quarter Performance It's time to grab your investing gear because Hyperliquid Strategies Inc is ready to spill the beans on their Q3 2026 performance. The digital asset treasury focused on the hyperventilating HYPE token—fined-tuned to serve US and institutional investors—is broadcasting a live webcast on November 5, 2026. Mark your...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 57

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Veterans Find Community and Wellness at Orland Hills Bash

Updated Category News Views 16

A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Best Buddies Challenge Hits $4M For Inclusion

Updated Category News Views 7

A Record-Breaking Year for Best Buddies Everyone loves a good underdog story, and every now and then, you get one that really hits home. The 27th Annual Best Buddies Challenge in Hyannis Port did exactly that, raking in a whopping $4 million and drawing a crowd of nearly 1,000 participants. The event serves as both a fundraiser and a community builder, spotlighting its...

Continue Reading
MSP Recovery Implements Reverse Stock Split for Compliance

Updated Category News Views 239

MSP Recovery Announces a Reverse Stock Split MSP Recovery, Inc. (NASDAQ: MSPR), a leader in Medicare, Medicaid, and secondary payer reimbursement recovery, recently announced a reverse stock split of its Class A common stock at a ratio of 1-for-7. This strategic move aims to ensure compliance with Nasdaq's minimum bid price requirement. Details of the Stock Split The...

Continue Reading
The Value of a $1000 Investment in Primerica Over 10 Years

Updated Category News Views 127

Understanding Primerica's Growth Over the Last Decade Primerica Inc (NYSE: PRI) has shown remarkable performance, outperforming the market by an annualized rate of 8.02%. This impressive rate results in an average annual return of 19.51% for the investors over the past ten years. As of now, the company has a market valuation of approximately $8.63 billion, indicating...

Continue Reading
Innovative G-Rex Grants Propel Cell Therapy Manufacturing Growth

Updated Category News Views 161

Innovative G-Rex Grants Propel Cell Therapy Manufacturing Growth ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), has announced an exciting initiative aimed at enhancing cell and gene therapy manufacturing. Eight G-Rex Grants, amounting to nearly $2 million, have been awarded to distinguished recipients within the...

Continue Reading